First-in-human use of the OneShot™ renal denervation System from Covidien

EuroIntervention

Volumn 8, Issue 9, 2013, Pages 1090-1093

  Ormiston, John A ^a,b   Watson, Timothy ^b   Van Pelt, Niels ^c   Stewart, Ralph ^a,b   Haworth, Peter ^b   Stewart, James T ^a,b   Webster, Mark W I ^a,b  

^a Mercy Angiography ^*  (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c Division of Medicine Emergency and Integrated Care   (New Zealand)

Author keywords

Hypertension; Radiofrequency ablation; Renal Denervation

Indexed keywords

DOXAZOSIN; METHYLDOPA; METOPROLOL; QUINAPRIL;

AGED; AORTOGRAPHY; ARTICLE; BALLOON CATHETER; BLOOD CLOTTING TIME; CASE REPORT; CATHETER ABLATION; FEMALE; FLUOROSCOPY; GUIDE WIRE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; KIDNEY DENERVATION; MEDICAL DEVICE; RENAL ARTERY; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; THORAX PAIN;

AGED; BLOOD PRESSURE; CATHETER ABLATION; FEMALE; HUMANS; HYPERTENSION; RENAL ARTERY; SYMPATHECTOMY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84873102784     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV8I9A166     Document Type: Article

References (8)

1. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-9.
2. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-7.
3. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305-15. (Pubitemid 33016494)
4. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940-6.
5. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, Hoppe UC. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901-9.
6. Witkowski A, Prejbisz A, Florczak E, Ka̧dziela J, Śliwiński P, Bieleń P, Michałowska I, Kabat M, Warchoł E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559-65.
7. Masuo K, Lambert GW, Esler MD, Rakugi H, Ogihara T, Schlaich MP. The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens Res. 2010;33:521-8.
8. Franchitto N, Despas F, Labrunée M, Roncalli J, Boveda S, Galinier M, Senard JM, Pathak A. Tonic chemoreflex activation contributes to increased sympathetic nerve activity in heart failurerelated anemia. Hypertension. 2010;55:1012-7.